Trading Analysis Report: ISRG
- Analysis date: 2026-05-31
- Processed decision: Buy
- Price Target: 480
I. Analyst Team Reports
Market Analyst
Market Report
Intuitive Surgical (ISRG) closed at $424.64 on May 29, 2026. yfinance showed a 52-week range of $414.30-$603.88, a 50-day average of $453.94, and a 200-day average of $495.04.
The stock has corrected sharply despite strong operating results. The local yfinance history showed a -23.1% one-year return and -24.4% YTD return.
StockAnalysis ranked ISRG #22 on its AI stocks list by market capitalization, reflecting its exposure to robotic-assisted surgery and digitally enabled healthcare automation.
Market read: the business is compounding, while the stock has reset closer to the 52-week low. Assign Buy with a $480 target.
Sentiment Analyst
Sentiment Report
Sentiment toward ISRG is mixed but improving.
The bull narrative is durable procedure growth, da Vinci 5 adoption, Ion growth, high recurring instruments and accessories revenue, and a debt-free balance sheet.
The bear narrative is valuation. yfinance still showed a 51.53x trailing P/E and 14.21x price/sales, even after the share-price decline.
The stock is below both the 50-day and 200-day averages, so market sentiment is not yet fully repaired.
Sentiment read: Buy is appropriate for long-term quality after the drawdown, but the target should stay disciplined.
News Analyst
News Report
The key current source is Intuitive Surgical's Q1 2026 earnings release.
Intuitive reported Q1 2026 revenue of $2.77 billion, up 23% year over year. Worldwide procedures grew approximately 17%, with da Vinci procedures up approximately 16% and Ion procedures up approximately 39%.
The company placed 431 da Vinci systems in Q1 2026 versus 367 in Q1 2025. Da Vinci 5 placements were 232, up from 147 in the prior-year quarter.
The da Vinci installed base reached 11,395 systems, up 12%, and the Ion installed base reached 1,041 systems, up 22%.
News read: ISRG is still executing well operationally, with procedure growth and platform adoption offsetting some valuation risk.
Fundamentals Analyst
Fundamentals Report
ISRG's fundamentals remain high quality.
Q1 2026 GAAP net income attributable to Intuitive Surgical was $822 million, or $2.28 per diluted share. Non-GAAP net income was $901 million, or $2.50 per diluted share.
Revenue mix remains attractive. Instruments and accessories revenue was $1.69 billion, up 23% year over year; systems revenue was $651 million; and services revenue was $433.7 million.
The balance sheet is strong. Intuitive ended Q1 2026 with $7.98 billion in cash, cash equivalents, and investments, and yfinance showed $0 total debt.
The main fundamental issue is price. yfinance showed a 51.53x trailing P/E and 36.01x forward P/E.
Fundamental read: Buy because growth, margins, and balance sheet quality support a premium, but the target should not assume a full return to the 52-week high.
II. Research Team Decision
Bull Researcher
Bull Research
The bull case is that ISRG remains the category leader in robotic-assisted surgery.
Procedure growth was approximately 17% in Q1 2026, and da Vinci 5 placements increased to 232 systems from 147 a year earlier.
The installed base creates recurring revenue through instruments, accessories, and services. Instruments and accessories revenue alone reached $1.69 billion in Q1 2026.
The company also has a strong cash position and no debt in the yfinance snapshot.
Bull conclusion: ISRG can recover toward $480-$500 if procedure growth and da Vinci 5 adoption continue.
Bear Researcher
Bear Research
The bear case is valuation and trend damage.
The stock remains below the $453.94 50-day average and $495.04 200-day average. It is also still expensive at 51.53x trailing earnings and 14.21x sales in the yfinance snapshot.
Hospital capital spending, tariffs, regulatory timing, competition, procedure mix, and international reimbursement can pressure results.
The company guided 2026 non-GAAP gross margin to 67.5%-68.5%, including an estimated tariff impact of 1.0% of revenue.
Bear conclusion: the business is strong, but upside should be sized conservatively.
Research Manager
Research Manager Synthesis
The bull case is recurring procedure-driven revenue, da Vinci 5 adoption, Ion growth, high margins, and a debt-free balance sheet.
The bear case is high valuation, weak stock momentum, tariff pressure, and healthcare capital-spending risk.
The correct conclusion is Buy, but not an aggressive one. The $480 target is below the 200-day average and far below the 52-week high, while still offering attractive upside from the latest close.
Synthesis: assign Buy with a $480 target.
III. Trading Team Plan
Trader
Trader View
ISRG is a quality-growth recovery trade.
The stock is near the lower end of its 52-week range and below major moving averages, so confirmation is still needed.
Upside trigger: stronger procedure data, continued da Vinci 5 placements, stable gross margin despite tariffs, and a move back above the 50-day average.
Downside trigger: slower hospital spending, gross-margin pressure, lower procedure growth, or a break below the 52-week low.
Trading plan: Buy with a $480 6-12 month base-case target.
IV. Risk Management Team Decision
Aggressive Analyst
Aggressive Risk View
Aggressive investors can buy ISRG on the pullback because operating momentum remains strong.
The risk is that a high-multiple stock can stay weak if growth-stock sentiment remains pressured.
Aggressive conclusion: Buy.
Conservative Analyst
Conservative Risk View
Conservative investors should respect valuation risk.
ISRG has no debt in the yfinance snapshot and strong recurring revenue, but the P/E and price/sales multiples remain elevated.
Conservative conclusion: Buy only with moderate sizing.
Neutral Analyst
Neutral Risk View
The neutral view balances quality and valuation.
Q1 execution was strong, but the market is still discounting the stock below the 50-day and 200-day averages.
The $480 target reflects partial recovery rather than a full rerating.
Neutral conclusion: Buy.
V. Portfolio Manager Decision
Portfolio Manager
Portfolio Manager Decision
Rating: Buy Price Target: 480
Horizon: 6-12 months Current Price Reference: $424.64 close on 2026-05-29
Intuitive Surgical is rated Buy. ISRG is a high-quality robotic-assisted surgery leader included in the web-researched AI stock universe, and the stock's drawdown has improved the risk/reward.
Intuitive reported Q1 2026 revenue of $2.77 billion, up 23% year over year. Worldwide procedures grew approximately 17%, da Vinci procedures grew approximately 16%, and Ion procedures grew approximately 39%.
The company placed 431 da Vinci surgical systems in Q1 2026, including 232 da Vinci 5 systems. The da Vinci installed base reached 11,395 systems, up 12% year over year, while the Ion installed base reached 1,041 systems, up 22%.
Q1 2026 GAAP net income attributable to Intuitive Surgical was $822 million, or $2.28 per diluted share. Non-GAAP net income was $901 million, or $2.50 per diluted share.
yfinance showed a latest close of $424.64, market cap of approximately $150.39 billion, trailing P/E of 51.53x, forward P/E of 36.01x, price/sales of 14.21x, total cash of $4.52 billion, and total debt of $0.
The main risks are valuation, weak stock momentum, tariffs, hospital capital-spending cycles, regulatory timing, reimbursement, and competition.
The $480 target represents a partial recovery and remains below the 200-day average and far below the 52-week high. Buy is appropriate because ISRG's procedure growth, recurring revenue model, and balance sheet quality justify a premium after the stock reset.